Pathology
 |
|
25 september 2018 07:02:56 |
| Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (Leukemia) |
|
Tweet |
| 60 viewsCategory: Pathology |
 Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization (Leukemia)Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis (Leukemia) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
